Relatlimab is a monoclonal human antibody that targets the Lymphocyte activation gene-3 (LAG-3).
Routes of administration Intravenous
An Antineoplastic agent.
Used only in combination with nivolumab.
Relatlimab is a monoclonal antibody designed for the treatment of melanoma in combination with nivolumab.
Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor.
The combination nivolumab/relatlimab (Opdualag) is approved for medical use.